γ-Aminobutyric acid mimetic drugs differentially inhibit the dopaminergic response to cocaine

European Journal of Pharmacology

Volumn 395, Issue 2, 2000, Pages 129-135

  Gerasimov, Madina R ^a   Schiffer, Wynne K ^a   Brodie, Jonathan D ^a   Lennon, Ian C ^a   Taylor, Stephen J C ^a   Dewey, Stephen L ^a  

^a BROOKHAVEN NATIONAL LABORATORY   (United States)

Author keywords

Cocaine; Dopamine; Microdialysis; Aminobutyric acid (GABA); Aminobutyric acid (GABA) reuptake inhibitor; Vinyl GABA (vigabatrin)

Indexed keywords

1 [2 (BENZHYDRYLIDENEAMINOOXY)ETHYL] 1,2,5,6 TETRAHYDRO 3 PYRIDINECARBOXYLIC ACID; 4 AMINO 3 CYCLOPENTE 1 CARBOXYLIC ACID; 4 AMINOBUTYRATE AMINOTRANSFERASE INHIBITOR; ANTICONVULSIVE AGENT; COCAINE; UNCLASSIFIED DRUG; VIGABATRIN;

4 AMINOBUTYRIC ACID UPTAKE; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DOPAMINE RELEASE; DOPAMINERGIC ACTIVITY; GABAERGIC SYSTEM; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; MALE; MICRODIALYSIS; NONHUMAN; NUCLEUS ACCUMBENS; PRIORITY JOURNAL; RAT; REINFORCEMENT;

ANIMALS; COCAINE; DOPAMINE UPTAKE INHIBITORS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; GABA ANTAGONISTS; GAMMA-AMINOBUTYRIC ACID; MALE; MICRODIALYSIS; MOLECULAR MIMICRY; NIPECOTIC ACIDS; OXIMES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, DOPAMINE; SODIUM CHLORIDE;

EID: 0034725028     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(00)00267-3     Document Type: Article

References (41)

1. Borden L.A., Murali Dhar T.G., Smith K.E., Weinshank R.L., Branchek T.A., Gluchowski C. Tiagabine, SK&F 89976-A, CI-966, and NNC-711 are selective for the cloned GABA transporter GAT-1. Eur. J. Pharmacol. 269:1994;219-224.
2. Braestrup C., Nielsen E.B., Sonnewald U., Knutsen L.J., Andersen K.E., Jansen J.A., Frederiksen K., Andersen P.H., Mortensen A., Suzdak P.D. (R)-N-[4,4-bis(3-methyl-2-thienyl)but-3-en-1-yl]nipecotic acid binds with high affinity to the brain gamma-aminobutyric acid uptake carrier. J. Neurochem. 54:1990;639-647.
3. Campbell U.C., Lac S.T., Carroll M.E. Effects of baclofen on maintenance and reinstatement of intravenous cocaine self-administration in rats. Psychopharmacology. 143:1999;209-214.
4. Christensen H., Fykse E.M., Fonnum F. Inhibition of famma-aminobutyrate and glycine uptake into synaptic vesicles. Eur. J. Pharmacol. 207:1991;73-79.
5. Costa E., Guidotti A. Benzodiazepines on trial: a research stragegy for their rehabilitation. TIPS. 17:1996;192-200.
6. Dam M. Long term evaluation of vigabatrin (gamma vinyl-GABA) in epilepsy. Epilepsia. 30:1989;S26-S30.
7. Dewey S.L., Smith G.S., Logan J., Brodie J.D., Yu D.W., Ferrieri R.A., King P.T., MacGregor R.R., Martin T.P., Wolf A.P. GABAergic inhibition of endogenous dopamine release measured in vivo with 11C-raclopride and positron emission tomography. J. Neurosci. 12:1992;3773-3780.
8. Dewey S.L., Chaurasia C.S., Chen C.E., Volkow N.D., Clarkson F.A., Porter S.P., Straughter-Moore R.M., Alexoff D.L., Tedeschi D., Russo N.B., Fowler J.S., Brodie J.D. GABAergic attenuation of cocaine-induced dopamine release and locomotor activity. Synapse. 25:1997;393-398.
9. Dewey S.L., Morgan A.E., Ashby C.R.J., Horan B., Kushner S.A., Logan J., Volkow N.D., Fowler J.S., Gardner E.L., Brodie J.D. A novel strategy for the treatment of cocaine addiction. Synapse. 30:1998;119-129.
10. Dewey S.L., Brodie J.D., Gerasimov M., Horan B., Gardner E.L., Ashby C.R.J. A pharmacologic strategy for the treatment of nicotine addiction. Synapse. 31:1999;76-86.
11. Engberg G., Klingpetersen T., Nissbrandt H. GABA(B) receptor activation alters the firing pattern of dopamine neurons in the rat substantia nigra. Synapse. 15:1993;229-238.
12. Fink-Jensen A., Suzdak P.D., Swedberg M.D., Judge M.E., Hansen L., Nielsen P.G. The gamma-aminobutyric acid (GABA) uptake inhibitor, tiagabine, increases extracellular brain levels of GABA in awake rats. Eur. J. Pharmacol. 220:1992;197-201.
13. Finlay J.M., Damsma G., Fibiger H.C. Benzodiazepine-induced decreases in extracellular concentrations of dopamine in the nucleus accumbens after acute and repeated administration. Psycopharmacology. 106:1992;202-208.
14. Gerasimov M.R., Ashby C.R., Gardner E.L., Mills M.J., Brodie J.D., Dewey S.L. Gamma-vinyl GABA inhibits methamphetamine, heroin, or ethanol-induced increases in nucleus accumbens dopamine. Synapse. 34:1999;11-19.
15. Gerrits M.A., Van Ree J.M. Effect of nucleus accumbens dopamine depletion on motivational aspects involved in initiation of cocaine and heroin self-administration in rats. Brain Res. 713:1996;114-124.
16. A receptor modulator, inhibits the effects of cocaine on locomotor activity and extracellular dopamine in the nucleus accumbens shell without tolerance liability. J. Pharmacol. Exp. Ther. 287:1998;58-66.
17. Gong W., Neill D.B., Justice J.B.J. GABAergic modulation of ventral pallidal dopamine release studied by in vivo microdialysis in the freely moving rat. Synapse. 29:1998;406-412.
18. Jolkkonen J., Mazurkiewicz M., Lahtinen H., Riekkinen P. Acute effects of gamma-vinyl GABA on the GABAergic system in rats as studied by microdialysis. Eur. J. Pharmacol. 229:1992;269-272.
19. Jung M.J., Lippert B., Metcalf B.W., Böhlen P., Schechter P.J. Gamma-vinyl GABA (4-amino-hex-5-enoic acid), a new selective irreversible inhibitor of GABA-T: effects on brain GABA metabolism in mice. J. Neurochem. 29:1977;797-802.
20. Kalivas P.W., Duffy P., Eberhardt H. Modulation of A10 dopamine neurons by gamma-aminobutyric acid agonists. J. Pharmacol. Exp. Ther. 253:1990;858-866.
21. Kälviäinen R. Tiagabine: a new therapeutic option for people with intellectual disability and partial epilepsy. J. Intellect. Disabil. Res. 42(Suppl. 1):1998;63-67.
22. Krogsgaard-Larsen P., Johnston G.A. Inhibition of GABA uptake in rat brain slices by nipecotic acid, various isoxazoles and related compounds. J. Neurochem. 25:1975;797-802.
23. Kuhar M.J., Ritz M.C., Boja J.W. The dopamine hypothesis of the reinforcing properties of cocaine. TIPS. 14:1991;299-302.
24. Kushner S.A., Dewey S.L., Kornetsky C. The irreversible gamma-aminobutyric acid (GABA) transaminase inhibitor gamma-vinyl GABA blocks cocaine self administration in rats. J. Pharmacol. Exp. Ther. 290:1999;797-802.
25. Meririnne E., Kankaanpää A., Lillsunde P., Seppälä T. The effects of diazepam and zolpidem on cocaine- and amphetamine-induced place preference. Pharmacol. Biochem. Behav. 62:1999;159-164.
26. Morgan A.E., Dewey S.L. Effects of pharmacologic increases in brain GABA levels on cocaine-induced changes in extracellular dopamine. Synapse. 28:1998;60-65.
27. Morgan A.E., Porter S.P., Clarkson F.A., Volkow N.D., Fowler J.S., Dewey S.L. Direct approach for attenuating cocaine's effects on extracellular dopamine: targeting the dopamine transporter. Synapse. 26:1997;423-427.
28. Nielsen E.B., Suzdak P.D., Andersen K.E., Knutsen L.J., Sonnewald U., Braestrup C. Characterization of tiagabine (NO-328), a new potent and selective GABA uptake inhibitor. Eur. J. Pharmacol. 196:1991;257-266.
29. Parsons L.H., Justice J.B.J. Serotonin and dopamine sensitization in the nucleus accumbens, ventral tegmental area, and dorsal raphe nucleus following repeated cocaine administration. J. Neurochem. 61:1993;1611-1619.
30. Petroff O.A., Rothman D.L., Behar K.L., Mattson R.H. Human brain GABA levels rise after initiation of vigabatrin therapy but fail to rise further with increasing dose. Neurology. 46:1996;1459-1463.
31. Pettit H.O., Justice J.B.J. Effect of dose on cocaine self-administration behavior and dopamine levels in the nucleus accumbens. Brain Res. 539:1991;94-102.
32. Pettit H.O., Pan H.T., Parsons L.H., Justice J.B.J. Extracellular concentrations of cocaine and dopamine are enhanced during chronic cocaine administration. J. Neurochem. 55:1990;798-804.
33. Qui J., Pingstehaus J.M., Silverman R. Inhibition and substrate activity of conformationally rigid vigabatrin analogues with gamma-aminobutyric acid aminotransferase. J. Med. Chem. 2000;. (in press).
34. Roberts D.C., Andrews M.M., Vickers G.J. Baclofen attenuates the reinforcing effects of cocaine in rats. Neuropsychopharmacology. 15:1996;417-423.
35. Sabers A., Gram L. Pharmacology of vigabatrin. Pharmacol. Toxicol. 70:1992;237-243.
36. Scatton B., Zivkovic B., Dedek J., Lloyd K.G., Constantinidis J., Tissot R., Bartholini G. Gamma-aminobutyric acid (GABA) receptor stimulation. III. Effect of progabide (SL 76002) on norepinephrine, dopamine and 5-hydroxytryptamine turnover in rat brain areas. J. Pharmacol. Exp. Ther. 220:1982;678-688.
37. Segal D.S., Kuczenski R. Repeated cocaine administration induces behavioral sensitization and corresponding decreased extracellular dopamine responses in caudate and accumbens. Brain Res. 577:1992;351-355.
38. Suzdak P.D. Lipophilic GABA uptake inhibitors: Biochemistry, pharmacology and therapeutic potential. Drugs Future. 18:1993;1129-1136.
39. Suzdak P.D., Frederiksen K., Andersen K.E., Sørensen P.O., Knutsen L.J., Nielsen E.B. NNC-711, a novel potent and selective gamma-aminobutyric acid uptake inhibitor: pharmacological characterization. Eur. J. Pharmacol. 224:1992;189-198.
40. Takada K., Yanagita T. Drug dependence study on vigabatrin in rhesus monkeys and rats. Arzneim.-Forsch./Drug Res. 47:1997;1087-1092.
41. A receptors-an in vivo electrochemical study. Brain Res. 798:1998;156-165.